AOBO is a pharmaceutical company engaged in improving health through the manufacture, development and commercialisation of prescription and over-the-counter (OTC) products.
AOBO has posted a net income of $5.32m for the third quarter 2010, or $0.07 per diluted share, compared to net income of $10.03m, or $0.13 per diluted share, for the comparable period in 2009.
Income from operations was $8.97m, compared to $15m for the comparable period in 2009.
AOBO has posted a revenue of $222.58m, for the nine months ended 30 September 2010, compared to $196.12m for the year ago period.
For the nine months ended 30 September 2010, AOBO has posted a net income of $13.56m, or $0.18 per diluted share, compared to $29.63m, or $0.39 per diluted share, for the year ago period.
AOBO chairman and CEO Tony Liu said that they were glad to report double digit revenue growth despite continuing macro challenges.
"We are also pleased to report that our Jinji Capsule was awarded status as ‘the most recognised brand in Women’s Healthcare Products in China’ for 2010 by China Pharmaceutical Enterprise Co-operation and Development organisation, China Pharmaceutical Research Center of Retailing, and 21 century pharmacy news and retail outlets media," Liu said.